STOCK TITAN

Armistice Capital and Steven Boyd Disclose 1.53M ANGO Shares

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G/A

Rhea-AI Filing Summary

Armistice Capital and Steven Boyd report a passive 3.76% stake in AngioDynamics (ANGO). The filing states Armistice Capital, as investment manager to Armistice Capital Master Fund Ltd., and Steven Boyd, as managing member, share voting and dispositive power over 1,527,815 shares. The stake is based on 40,633,885 shares outstanding as of May 31, 2025, per the issuer's 10-K. The Reporting Persons state the holdings were acquired in the ordinary course of business and not to influence control of the company. The Master Fund is the direct holder while Armistice exercises voting and investment authority under an investment management agreement.

Positive

  • Transparent disclosure of beneficial ownership and the relationship between Armistice Capital, the Master Fund, and Steven Boyd
  • Position is passive and under 5%, indicating no immediate intent to influence control

Negative

  • None.

Insights

TL;DR: Institutional manager reports a non-controlling 3.76% position, disclosed for regulatory transparency.

The Schedule 13G/A shows Armistice Capital, via its Master Fund, holds 1,527,815 AngioDynamics shares representing 3.76% of the reported float. This level is below the 5% threshold that typically triggers Schedule 13D obligations, indicating a passive investor posture. The filing clarifies voting and dispositive powers are exercised by Armistice under an investment management agreement and that holdings are ordinary-course investments, which reduces the likelihood of imminent activism or control attempts.

TL;DR: Disclosure aligns with governance norms; no material control implications.

The joint filing and certifications are standard: Armistice and Steven Boyd file jointly and disclaim control beyond managerial authority. The explicit statement that the Master Fund disclaims beneficial ownership due to its agreement with Armistice is important for legal clarity. Because the position is under 5% and accompanied by a passive declaration, this is a routine ownership disclosure with limited immediate governance impact.






Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)






SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G



Armistice Capital, LLC
Signature:/s/ Steven Boyd
Name/Title:Steven Boyd - Managing Member
Date:08/14/2025
Steven Boyd
Signature:/s/ Steven Boyd
Name/Title:Steven Boyd
Date:08/14/2025
Exhibit Information

JOINT FILING STATEMENT PURSUANT TO RULE 13d-1(k) The undersigned acknowledge and agree that the foregoing statement on Schedule 13G, is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G, shall be filed on behalf of each of the undersigned without the necessity of filing additional joint acquisition statements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning him or it contained therein, but shall not be responsible for the completeness and accuracy of the information concerning the others, except to the extent that he or it knows or has reason to believe that such information is inaccurate. Dated: August 14, 2025 Armistice Capital, LLC By: /s/ Steven Boyd Steven Boyd - Managing Member Steven Boyd By: /s/ Steven Boyd

FAQ

How many AngioDynamics (ANGO) shares does Armistice Capital report owning?

The filing reports 1,527,815 shares beneficially owned by the Reporting Persons.

What percentage of ANGO does the reported position represent?

The position represents 3.76% of the class, based on 40,633,885 shares outstanding as of May 31, 2025.

Does Armistice Capital claim control of AngioDynamics?

No. The filing states the holdings were acquired and are held in the ordinary course of business and not to change or influence control.

Who holds the shares directly and who manages voting rights?

The Armistice Capital Master Fund Ltd. is the direct holder; Armistice Capital, as investment manager, exercises voting and investment power under an investment management agreement.

When was the Schedule 13G/A signed?

The signatures are dated August 14, 2025.